BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho AS, Luu M, Barrios L, Chen I, Melany M, Ali N, Patio C, Chen Y, Bose S, Fan X, Mallen-St Clair J, Braunstein GD, Sacks WL, Zumsteg ZS. Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma. JAMA Oncol 2020;6:706-13. [PMID: 32134428 DOI: 10.1001/jamaoncol.2019.6851] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Yin L, Hou S, Hou LL, Pu CC. Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis. Endocrine 2023;79:331-41. [PMID: 36207552 DOI: 10.1007/s12020-022-03200-x] [Reference Citation Analysis]
2 Wu SS, Joshi N, Sharrett J, Rao S, Shah A, Scharpf J, Burkey B, Lamarre ED, Prendes B, Siperstein A, Shin J, Berber E, Jin J, Krishnamurthi V, Nasr C, Hong L, Buchberger DS, Woody N, Koyfman SA, Geiger JL. Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer: A Single-Institution Cohort Study With Predictive Nomogram. JAMA Otolaryngol Head Neck Surg 2023;149:79-86. [PMID: 36454559 DOI: 10.1001/jamaoto.2022.3781] [Reference Citation Analysis]
3 Zhang D, Zhu X, Jiang J. Papillary Thyroid Carcinoma With Breast and Bone Metastasis. Ear Nose Throat J 2022. [DOI: 10.1177/01455613221145273] [Reference Citation Analysis]
4 Wang Y, Liu L, Zhou P, Luo X, Liu H, Yang H. Activated partial thromboplastin time maybe associated with the prognosis of papillary thyroid carcinoma. Open Chemistry 2022;20:1074-1083. [DOI: 10.1515/chem-2022-0219] [Reference Citation Analysis]
5 Shi P, Yang D, Liu Y, Zhao Z, Song J, Shi H, Wu Y, Jing S. A protective factor against lymph node metastasis of papillary thyroid cancer: Female gender. Auris Nasus Larynx 2022. [DOI: 10.1016/j.anl.2022.10.001] [Reference Citation Analysis]
6 Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, Mallen-st. Clair J, Chen MM, Vasquez M, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZS, Braunstein GD, Sacks WL. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial. JAMA Oncol. [DOI: 10.1001/jamaoncol.2022.3875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Li W, Wang Y, Gao L, Feng R, Lv K, Wu X, Yang X, Li J, Cai S, Wang H. Sonographic characteristics of diffuse sclerosing variant of papillary thyroid carcinoma with histopathological correlation: a preliminary study.. [DOI: 10.21203/rs.3.rs-2003158/v1] [Reference Citation Analysis]
8 Rončević J, Janković Miljuš J, Išić Denčić T, Božić V, Živaljević V, Šelemetjev S, Đorić I. Predictive Significance of Two MMP-9 Promoter Polymorphisms and Acetylated c-Jun Transcription Factor for Papillary Thyroid Carcinoma Advancement. Diagnostics 2022;12:1953. [DOI: 10.3390/diagnostics12081953] [Reference Citation Analysis]
9 Sparano C, Moog S, Hadoux J, Dupuy C, Al Ghuzlan A, Breuskin I, Guerlain J, Hartl D, Baudin E, Lamartina L. Strategies for Radioiodine Treatment: What’s New. Cancers 2022;14:3800. [DOI: 10.3390/cancers14153800] [Reference Citation Analysis]
10 Li R, Yang X, Zhang J, Wang D, Cui X, Bai L, Zhao L, Cui W. The Association Between Subclinical Thyroid Dysfunction and Recurrence of Atrial Fibrillation After Catheter Ablation. Front Cardiovasc Med 2022;9:902411. [DOI: 10.3389/fcvm.2022.902411] [Reference Citation Analysis]
11 Hurley CM, Phoenix E, Duff G, Lennon P, Shelley OP. Incidental Thyroid Tumour during Surgical Tracheostomy in a Patient with Toxic Epidermal Necrolysis. Burns Open 2022. [DOI: 10.1016/j.burnso.2022.02.003] [Reference Citation Analysis]
12 Kim H, Oh YL, Chung JH, Hahn SY, Park KW, Kim TH, Shin JH. What is the difference between the tall cell variant and the classic type of papillary thyroid carcinoma on ultrasonography? Ultrasonography 2022. [PMID: 35430786 DOI: 10.14366/usg.21200] [Reference Citation Analysis]
13 Cheng S, Wu ATH, Batiha GE, Ho C, Lee J, Lukman HY, Alorabi M, Alrasheedi AN, Chen J. Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin. Biology 2022;11:324. [DOI: 10.3390/biology11020324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ignjatović VB, Janković Miljuš JR, Rončević JV, Tatić SB, Išić Denčić TM, Đorić IĐ, Šelemetjev SA. Focal adhesion kinase splicing and protein activation in papillary thyroid carcinoma progression. Histochem Cell Biol 2021. [PMID: 34817652 DOI: 10.1007/s00418-021-02056-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Xu J, Liao M. Long noncoding RNA SNHG6 promotes papillary thyroid cancer cells proliferation via regulating miR-186/CDK6 axis. Gland Surg 2021;10:2935-44. [PMID: 34804881 DOI: 10.21037/gs-21-586] [Reference Citation Analysis]
16 Tsybrovskyy O, De Luise M, de Biase D, Caporali L, Fiorini C, Gasparre G, Carelli V, Hackl D, Imamovic L, Haim S, Sobrinho-Simões M, Tallini G. Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors. J Pathol Clin Res 2021. [PMID: 34792302 DOI: 10.1002/cjp2.247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu Z, Zou Y, Sun Y, Chen X, Chen X, Ren Z. Effects of Nanosecond Pulsed Electric Fields in Cell Vitality, Apoptosis, and Proliferation of TPC-1 Cells. Anal Cell Pathol (Amst) 2021;2021:9913716. [PMID: 34692376 DOI: 10.1155/2021/9913716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nilsson JN, Siikanen J, Hedman C, Juhlin CC, Ihre Lundgren C. Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index. Cancers (Basel) 2021;13:3627. [PMID: 34298840 DOI: 10.3390/cancers13143627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Li Q, Jiang S, Feng T, Zhu T, Qian B. Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer. Onco Targets Ther 2021;14:3119-31. [PMID: 34012269 DOI: 10.2147/OTT.S301127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Xu M, Lin B, Zheng D, Wen J, Hu W, Li C, Zhang X, Zhang X, Qu J. LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. Oncol Lett 2021;21:442. [PMID: 33868480 DOI: 10.3892/ol.2021.12703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Toraih EA, Hussein MH, Zerfaoui M, Attia AS, Marzouk Ellythy A, Mostafa A, Ruiz EML, Shama MA, Russell JO, Randolph GW, Kandil E. Site-Specific Metastasis and Survival in Papillary Thyroid Cancer: The Importance of Brain and Multi-Organ Disease. Cancers (Basel) 2021;13:1625. [PMID: 33915699 DOI: 10.3390/cancers13071625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
22 Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, Dal Maso L. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol 2021;9:225-34. [PMID: 33662333 DOI: 10.1016/S2213-8587(21)00027-9] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 39.5] [Reference Citation Analysis]
23 Kitahara CM, Sosa JA, Shiels MS. Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017. J Clin Endocrinol Metab 2020;105:dgaa690. [PMID: 32984898 DOI: 10.1210/clinem/dgaa690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
24 Cartwright S, Fingeret A. Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes 2020;27:351-7. [PMID: 32701516 DOI: 10.1097/MED.0000000000000559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Li LR, Du B, Liu HQ, Chen C. Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives. Front Oncol 2020;10:604051. [PMID: 33634025 DOI: 10.3389/fonc.2020.604051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
26 Zhang D, Jones RR, James P, Kitahara CM, Xiao Q. Associations between artificial light at night and risk for thyroid cancer: A large US cohort study. Cancer 2021;127:1448-58. [PMID: 33554351 DOI: 10.1002/cncr.33392] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
27 Yang Z, Wei X, Pan Y, Xu J, Si Y, Min Z, Yu B. A new risk factor indicator for papillary thyroid cancer based on immune infiltration. Cell Death Dis 2021;12:51. [PMID: 33414407 DOI: 10.1038/s41419-020-03294-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
28 Ren X, Zhu D, Wang H, Wang J, Lin B, Ou Y, Huang B, Huang J. In the Basis of Hashimoto’s Thyroiditis, to Form Papillary Thyroid Carcinoma, Metastasized and Then to De-Differentiate into Poorly Differentiated Squamous Cell Carcinoma. JCT 2021;12:254-267. [DOI: 10.4236/jct.2021.125024] [Reference Citation Analysis]
29 Siraj AK, Parvathareddy SK, Qadri Z, Siddiqui K, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up. Cancers (Basel) 2020;12:E3624. [PMID: 33287340 DOI: 10.3390/cancers12123624] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
30 Bai Y, Kakudo K, Jung CK. Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. Endocrinol Metab (Seoul) 2020;35:696-715. [PMID: 33261309 DOI: 10.3803/EnM.2020.807] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
31 Feng JW, Ye J, Wu WX, Pan H, Qin AC, Jiang Y, Wu BQ. Management of Clinically Solitary Papillary Thyroid Carcinoma Patients According to Risk-Scoring Model for Contralateral Occult Carcinoma. Front Endocrinol (Lausanne) 2020;11:553577. [PMID: 33133013 DOI: 10.3389/fendo.2020.553577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Ho AS, Luu M, Barrios L, Balzer BL, Bose S, Fan X, Walgama E, Mallen-St Clair J, Alam U, Shafqat I, Lin DC, Chen Y, Van Eyk JE, Maghami EG, Braunstein GD, Sacks WL, Zumsteg ZS. Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma. Ann Surg Oncol 2021;28:1731-9. [PMID: 32808161 DOI: 10.1245/s10434-020-09023-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 Ochoa JE, Yeh MW, Livhits MJ. Aggressive Variants of Papillary Thyroid Cancer Are Increasing in Incidence and Have Heterogeneous Outcomes. Clinical Thyroidology 2020;32:284-6. [DOI: 10.1089/ct.2020;32.284-286] [Reference Citation Analysis]
34 Li GY, Tan HL, Chen P, Hu HY, Liu M, Ou-Yang DJ, Khushbu RA, Pun D, Li JD, Zhang ZP, Yang Q, Huang P, Chang S. Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAFV600E Mutation and Clinicopathological Features. Cancer Manag Res 2020;12:3371-8. [PMID: 32494201 DOI: 10.2147/CMAR.S247914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Error in Figure. JAMA Oncol 2020;6:789. [DOI: 10.1001/jamaoncol.2020.0896] [Reference Citation Analysis]